SUVENPHAR2022-10-012022-12-31 SUVENPHAR2022-10-012022-12-31 SUVENPHAR2022-10-012022-12-31in-bse-fin:OneOperatingExpenses01Member SUVENPHAR2022-10-012022-12-31in-bse-fin:OneOperatingExpenses02Member SUVENPHAR2022-10-012022-12-31in-bse-fin:OneOperatingExpenses03Member SUVENPHAR2022-10-012022-12-31in-bse-fin:FourOperatingExpenses01Member SUVENPHAR2022-10-012022-12-31in-bse-fin:FourOperatingExpenses02Member SUVENPHAR2022-10-012022-12-31in-bse-fin:FourOperatingExpenses03Member SUVENPHAR2022-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543064 SUVENPHAR NOTLISTED Suven Pharmaceuticals Limited Equity 2022-04-01 2023-03-31 2023-02-06 2023-01-30 INR Lakhs Third quarter 11:30:00 12:55:00 2023-02-06 2023-02-06 Not applicable Single segment Contract Development and Manufacturing Operations (CDMO) 2022-10-01 2022-12-31 Unaudited Standalone 3484890000.00 125105000.00 3609995000.00 1351642000.00 0.00 -265099000.00 272637000.00 13794000.00 109138000.00 655039000.00 2137151000.00 1472844000.00 0.00 1472844000.00 371523000.00 6659000.00 378182000.00 0.00 1094662000.00 0.00 0.00 0.00 0.00 1094662000.00 -1907000.00 1092755000.00 0.00 0.00 254565000.00 1 4.30 4.30 0.00 0.00 4.30 4.30 Notes: 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 6th February, 2023. The above results have been subjected to limited review by the statutory auditors of the company. 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 3) The consolidated financial results include the results of the wholly owned subsidiarIes Suven Pharma, Inc.,USA & Casper Pharma Pvt Ltd, (wef from 22nd April '2022). 4) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. 5) The other Income (Standalone figures for the year-2021-22 includes an amount of Rs.15081.85 Lacs (Q2 Rs.3329.39 lacs & Q4 Rs.11752.46 lacs) pertaining to the Dividends received and Rs.1080.41 lacs (Q4) pertaining to Gain on Investments on part disinvestment of Capital from our Wholly Owned Subsidiary, Suven pharma, Inc . The Current tax for the year 2021-22 (Standalone figures) includes an amount of Rs.1676.21 lacs (Q3 Rs.491.72 Lacs & Q4 Rs.1184.49 Lacs) withholding tax paid on such dividend by our wholly owned subsidiary. 6) The Suven Pharma Inc., the WOS of our Company has divested it's entire stake (25% amounting to $35.00 Mn) in M/s Rising pharma Holdings, Inc., USA on 13th Dec, 2021 to Raisin Acquisition Co, Inc., one of the investment arms of H.I.G. Capital, USA through structured deal. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of US $41.555 Mn and a stake valued at US $15.803 Mn in Raisin Aggregators, L.P. Accordingly, Rising Pharma Holdings, Inc., USA has ceased to be an associate company w.e.f 13th Dec'2021. 7) Post approval of the Board in the meeting held on 5th April 2022, the company has completed acquisition of 100% stake in Casper Pharma Pvt Ltd, (SEZ company) engaged in formulations business for US $20.50 Mn and has become a Wholly Owned Subsidiary of the Company w.e.f 22 nd April 2022. Subsequently subscribed the right issue in the ratio of 4:1 on 22/06/2022 of 52,16,156 shares of face value of Rs.10.00 with a premium of Rs.70.00 per share for Rs.4172.92 Lacs. 8) The Promoter Group, Jasti Property and Equity Holdings Private Limited (in their capacity as sole trustee of Jasti Family Trust), informed the Company that they executed a Share Purchase Agreement to sell 12,75,37,043 Equity shares representing 50.10% of the Voting share capital to Berhyanda Limited company on 26th December 2022. 9) The corresponding previous period figures have been regrouped/reclassified where ever necessary. Single segment 2022-04-01 2022-12-31 Unaudited Standalone 9656899000.00 337974000.00 9994873000.00 3317949000.00 0.00 -418210000.00 779432000.00 31022000.00 322173000.00 1893233000.00 5925599000.00 4069274000.00 0.00 4069274000.00 1016580000.00 28287000.00 1044867000.00 0.00 3024407000.00 0.00 0.00 0.00 0.00 3024407000.00 -5721000.00 3018686000.00 0.00 0.00 254565000.00 1 11.88 11.88 0.00 0.00 11.88 11.88 Manufacturing Expenses 459926000.00 Other Expenses 172414000.00 R & D expense 22699000.00 Manufacturing Expenses 1318747000.00 Other Expenses 508718000.00 R & D expense 65768000.00 -2548000.00 -7645000.00 -641000.00 -1924000.00 0.00 0.00